PathoQuest

Executive Summary

PathoQuest is a French biotechnology company founded in 2010 that specializes in GMP-grade biosafety testing and quality control for biopharmaceuticals. Using its proprietary iDTECT® platform, based on next-generation sequencing (NGS), the company provides comprehensive viral safety screening and genetic characterization assays. Operating as a specialized Contract Research Organization (CRO), PathoQuest serves global biopharma companies, contract development and manufacturing organizations (CDMOs), and emerging biotechs, addressing the critical need for sensitive and rapid detection of adventitious agents in biologic manufacturing. The company's NGS-based approach offers advantages over traditional methods, including higher sensitivity, broader coverage, and faster turnaround times. As regulatory agencies increasingly accept NGS data for viral safety, PathoQuest is well-positioned to capture market share from conventional PCR and cell-based assays. With the growing complexity of biologic pipelines and heightened scrutiny on viral contamination, demand for advanced biosafety testing is expected to rise. PathoQuest's established platform, GMP compliance, and strategic location in the European biopharma hub position it for continued growth, though it operates in a competitive landscape with larger CROs and emerging NGS testing players.

Upcoming Catalysts (preview)

• Q2 2026Publication of validation data for iDTECT platform with a major regulatory agency (e.g., EMA or FDA)60% success
• Q3 2026Strategic partnership or multi-year contract with a top-10 CDMO50% success
• Q4 2026Expansion of service offerings to include additional NGS-based characterization assays for gene therapy vectors75% success